OpGen
Corporate Overview
January 10, 2022
OpGen, Inc.
Forward Looking Statements Disclaimer
This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1955. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond OpGen's control, and that may cause results to differ materially from expectations.
Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the continued impact of COVID-19 on the Company's operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward- looking statement, whether as a result of new information, future events or otherwise.
OpGen, Inc. | 2 |
OpGen Overview
Striving to innovate molecular microbiology
Fast | Comprehensive | Smart | Easy | ||
Rapid Pathogen | Broad Pathogen & | AI-Powered AMR | Sample-To-Answer |
Detection For Life | Antimicrobial | Prediction & | Platforms |
Threatening Infections | Resistance (AMR) | Bioinformatics | |
Marker Coverage |
OpGen, Inc. | 3 |
OpGen's combined portfolio
Synergistic products and capabilities
Unyvero Platform & | Acuitas AMR | Global Commercial | Ares Genetics NGS & | ||
Syndromic Tests | Gene Panel | Presence | Bioninformatics | ||
FDA-cleared LRT & LRT BAL for | FDA-cleared Acuitas AMR Gene | Direct sales and marketing in the |
lower respiratory tract infections | Panel for isolates | U.S. |
5 CE-IVD tests | Supports targeted antibiotic | EMEA, APAC, Latin America and |
Unyvero A30 RQ platform in | decision making & ASP program | China distribution with partners |
advanced stages of development | Enhances diagnostic capabilities | |
to manage patients with AMR | ||
days earlier than conventional | ||
AST |
OpGen, Inc.
AI-powered AMR prediction combining ARESdb with NGS
Strategic partnerships and collaborations with globally leading microbiology, IVD & pharma companies, as well as U.S. based CLIA Lab / CRO
4
OpGen's strategic positioning and benefits
Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms
Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics
Global commercial channel capabilities & partners
Financial leverage, operational synergies, and positive growth-driven business outlook
OpGen, Inc. | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
OpGen Inc. published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 12:47:02 UTC.